Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
TENX's Cash-to-Debt is ranked higher than
95% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. TENX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TENX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 40.42 Max: No Debt
Current: No Debt
0
No Debt
Interest Coverage No Debt
TENX's Interest Coverage is ranked higher than
94% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TENX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TENX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -52.09
Beneish M-Score: -4.54
WACC vs ROIC
10.76%
-741.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -77.53
TENX's ROE % is ranked lower than
61% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. TENX: -77.53 )
Ranked among companies with meaningful ROE % only.
TENX' s ROE % Range Over the Past 10 Years
Min: -516.91  Med: -100.32 Max: -18.37
Current: -77.53
-516.91
-18.37
ROA % -71.08
TENX's ROA % is ranked lower than
66% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. TENX: -71.08 )
Ranked among companies with meaningful ROA % only.
TENX' s ROA % Range Over the Past 10 Years
Min: -462.66  Med: -182.87 Max: -15.97
Current: -71.08
-462.66
-15.97
ROC (Joel Greenblatt) % -26068.97
TENX's ROC (Joel Greenblatt) % is ranked lower than
91% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. TENX: -26068.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TENX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -63489.66  Med: -3487.12 Max: -464.45
Current: -26068.97
-63489.66
-464.45
3-Year Revenue Growth Rate -100.00
TENX's 3-Year Revenue Growth Rate is ranked lower than
92% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. TENX: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TENX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 144.5
Current: -100
0
144.5
3-Year EBITDA Growth Rate 43.80
TENX's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. TENX: 43.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TENX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -43.2  Med: 19.1 Max: 56.2
Current: 43.8
-43.2
56.2
3-Year EPS without NRI Growth Rate 51.30
TENX's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. TENX: 51.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TENX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -85.7  Med: 14.8 Max: 67.1
Current: 51.3
-85.7
67.1
GuruFocus has detected 2 Warning Signs with Tenax Therapeutics Inc TENX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TENX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

TENX Guru Trades in Q1 2018

Jim Simons 57,200 sh (-45.37%)
» More
Q2 2018

TENX Guru Trades in Q2 2018

Jim Simons 83,400 sh (+45.80%)
» More
Q3 2018

TENX Guru Trades in Q3 2018

Jim Simons 87,700 sh (+5.16%)
» More
Q4 2018

TENX Guru Trades in Q4 2018

Jim Simons 164,741 sh (+87.85%)
» More
» Details

Insider Trades

Latest Guru Trades with TENX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Tenax Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541714    SIC: 8731
Compare:BOM:511509, OSTO:2CUREX, OTCPK:ISCO, TSXV:BCT, OTCPK:MATN, OTCPK:MRNA, XCNQ:NSHS, TSXV:RVV, OSTO:IVACC, OTCPK:LIXT, ASX:SCU, XTAE:XTL, ASX:PIQ, ROCO:6487, NAS:EARS, OTCPK:RGIN, XSAT:EUCI, ASX:NC6, ROCO:4135, ASX:LCT » details
Traded in other countries:YBOC.Germany,
Headquarter Location:USA
Tenax Therapeutics Inc is a specialty pharmaceutical company. The Company is engaged in developing & commercializing pharmaceutical products for critical care patients and its products include Levosimendan & Oxycyte.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The company develops novel product candidates such as Levodimendan and oxycyte that have the potential to address various critical care conditions with high unmet medical need. Its drugs help in the reduction of morbidity and mortality in cardiac surgery patients. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure.

Ratios

vs
industry
vs
history
PB Ratio 0.54
TENX's PB Ratio is ranked higher than
91% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. TENX: 0.54 )
Ranked among companies with meaningful PB Ratio only.
TENX' s PB Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.3 Max: 47.77
Current: 0.54
0.02
47.77
EV-to-EBIT -0.10
TENX's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. TENX: -0.10 )
Ranked among companies with meaningful EV-to-EBIT only.
TENX' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.8  Med: -4.2 Max: 1.4
Current: -0.1
-16.8
1.4
EV-to-EBITDA -0.10
TENX's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. TENX: -0.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
TENX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17  Med: -4.2 Max: 1.4
Current: -0.1
-17
1.4
Current Ratio 9.96
TENX's Current Ratio is ranked higher than
93% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. TENX: 9.96 )
Ranked among companies with meaningful Current Ratio only.
TENX' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 2.54 Max: 51.21
Current: 9.96
0.11
51.21
Quick Ratio 9.96
TENX's Quick Ratio is ranked higher than
93% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. TENX: 9.96 )
Ranked among companies with meaningful Quick Ratio only.
TENX' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 2.49 Max: 51.21
Current: 9.96
0.11
51.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
TENX's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. TENX: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TENX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -185.1  Med: -26 Max: 0
Current: -0.5
-185.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.61
TENX's Price-to-Net-Cash is ranked higher than
92% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. TENX: 0.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TENX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.6  Med: 13.26 Max: 7649.95
Current: 0.61
0.6
7649.95
Price-to-Net-Current-Asset-Value 0.57
TENX's Price-to-Net-Current-Asset-Value is ranked higher than
93% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. TENX: 0.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TENX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.56  Med: 14.02 Max: 481.89
Current: 0.57
0.56
481.89
Price-to-Tangible-Book 0.54
TENX's Price-to-Tangible-Book is ranked higher than
93% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. TENX: 0.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TENX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.52  Med: 8.56 Max: 685.71
Current: 0.54
0.52
685.71
Earnings Yield (Greenblatt) % -1010.45
TENX's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. TENX: -1010.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TENX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1277.53  Med: -18.4 Max: 3003.4
Current: -1010.45
-1277.53
3003.4

More Statistics

EPS (TTM) $ -4.12
Beta1.37
Volatility75.53%
52-Week Range $1.03 - 11.92
Shares Outstanding (Mil)3.02

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

» More Articles for TENX

Headlines

Articles On GuruFocus.com
3 Stocks Move Heavily on Wednesday Apr 04 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}